Background and Objectiue: Little information is available regarding the effectiveness of laser prostatectomy in patients with urinary retention from benign prostatic hyperplasia since there is no paper specifically dealing with laser prostatectomy in patients in urinary retention. Study DesignJMater
Nd:YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy
✍ Scribed by Dr. Anthony J. Costello; Douglas E. Johnson; Damien M. Bolton
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 393 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0196-8092
No coin nor oath required. For personal study only.
✦ Synopsis
Many techniques have been used to relieve obstructive symptoms associated with benign prostatic hypertrophy. Transurethral resection of the prostate (TURP) with an electrocautery loop is the most commonly performed operation to relieve bladder neck and urethral obstruction caused by prostatic adenoma. There is increased interest in alternative therapies to reduce prostatic size for symptom relief in this condition. We describe a technique using the neodymium:YAG (NdYAG) laser and a 600-pm laser quartz fibre with an attached terminal gold-plated metal alloy reflector to provide reliable deep penetration into prostatic tissue for prostatic adenoma ablation. We report the first use of this technique in three patients with benign prostatic obstruction and one with localised adenocarcinoma of the prostate.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND. Early detection of small‐volume prostate cancer (PCa) has led to the concept of focal therapy to treat PCa as an organ‐sparing, minimally invasive procedure. The authors sought to determine the frequency of unilateral cancers in the contemporary prostate‐specific antigen
## Abstract This report describes an improved synthesis of enantiomerically pure (__S__)‐2‐[4‐(Dimethylamino)phenyl]‐2,3‐dihydro‐__N__‐[2‐hydroxy‐3‐[4‐[2‐(1‐methylethoxy)‐phenyl]‐1‐piperazinyl]propyl]‐1,3‐dioxo‐1__H__‐isoindole‐5‐carboxamide (RWJ 69442), a potent and selective α~la~‐adrenergic rece
## Aims: To investigate urodynamically the effects of silodosin, a new alpha(1a)-adrenoceptor-selective antagonist, in the treatment of benign prostatic hyperplasia (bph). ## Methods: Thirty six male patients with bph (69.9 +/- 7.3 years), who were referred as candidates for surgery, were treated
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v